https://melaneconsulting.ch/ monthly 1.0 https://melaneconsulting.ch/services monthly 0.9 https://melaneconsulting.ch/about yearly 0.7 https://melaneconsulting.ch/blog weekly 0.8 https://melaneconsulting.ch/contact yearly 0.6 https://melaneconsulting.ch/book yearly 0.5 https://melaneconsulting.ch/blog/advancell-closes-315-million-series-d-for-lead-212-radiopharma 2026-07-17 monthly 0.7 https://melaneconsulting.ch/blog/ai-moves-from-drug-discovery-into-routine-manufacturing-optimisation 2026-07-12 monthly 0.7 https://melaneconsulting.ch/blog/annex-22-risk-classification 2026-05-28 monthly 0.7 https://melaneconsulting.ch/blog/astrazeneca-licenses-dizal-egfr-drug-zegfrovy-for-600-million-upfront 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/avere-therapeutics-to-go-public-via-nextcure-merger-with-320-million 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/biogen-and-ionis-post-phase-2-tau-data-for-diranersen-in-alzheimer-s 2026-07-19 monthly 0.7 https://melaneconsulting.ch/blog/bora-biologics-adds-a-rockville-site-scaling-us-single-use-capacity-to 2026-07-13 monthly 0.7 https://melaneconsulting.ch/blog/celcuity-wins-first-fda-approval-for-revtorpyk-in-breast-cancer 2026-07-16 monthly 0.7 https://melaneconsulting.ch/blog/celea-therapeutics-launches-with-180-million-one-of-2026-s-largest-deb 2026-07-02 monthly 0.7 https://melaneconsulting.ch/blog/chai-discovery-raises-400-million-series-c-for-ai-molecular-design 2026-07-19 monthly 0.7 https://melaneconsulting.ch/blog/codis-to-acquire-catalent-nottingham-site-in-european-spray-dry-push 2026-07-17 monthly 0.7 https://melaneconsulting.ch/blog/curifylabs-raises-14m-to-automate-3d-printed-pharmacy-compounding 2026-07-16 monthly 0.7 https://melaneconsulting.ch/blog/eli-lilly-to-buy-ataibeckley-for-up-to-3-8-billion-in-psychedelics-bet 2026-07-17 monthly 0.7 https://melaneconsulting.ch/blog/evonik-to-invest-100-million-in-us-api-and-hpapi-manufacturing 2026-07-17 monthly 0.7 https://melaneconsulting.ch/blog/fda-accepts-swiss-biotech-pharvaris-nda-for-deucrictibant-in-hereditar 2026-07-09 monthly 0.7 https://melaneconsulting.ch/blog/fda-approves-at-home-subcutaneous-leqembi-iqlik-for-early-alzheimer-s 2026-07-16 monthly 0.7 https://melaneconsulting.ch/blog/fda-approves-orca-bio-s-tregzi-first-regulatory-t-cell-therapy-to-cut 2026-07-05 monthly 0.7 https://melaneconsulting.ch/blog/fda-approves-utebzi-first-oral-carbapenem-for-complicated-utis 2026-07-19 monthly 0.7 https://melaneconsulting.ch/blog/fda-data-integrity-crackdown-widens-as-medline-warning-letter-lands 2026-07-16 monthly 0.7 https://melaneconsulting.ch/blog/fda-grants-accelerated-approval-to-atacicept-trutakna-for-iga-nephropa 2026-07-07 monthly 0.7 https://melaneconsulting.ch/blog/fda-posts-14-drug-rejection-letters-citing-quality-and-facility-gaps 2026-07-20 monthly 0.7 https://melaneconsulting.ch/blog/fda-proposes-rule-to-modernise-drug-manufacturing-registration 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/fmea-template-ai-tool-gmp 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/genmab-and-abbvie-s-epcoritamab-hits-its-primary-endpoint-in-phase-3-r 2026-07-03 monthly 0.7 https://melaneconsulting.ch/blog/innocare-s-soficitinib-meets-phase-3-goal-in-atopic-dermatitis 2026-07-20 monthly 0.7 https://melaneconsulting.ch/blog/insilico-and-bora-plan-2-5bn-ai-alliance-to-reach-drug-manufacturing 2026-07-16 monthly 0.7 https://melaneconsulting.ch/blog/ionis-and-astrazeneca-eplontersen-misses-phase-3-endpoint-in-attr-cm 2026-07-16 monthly 0.7 https://melaneconsulting.ch/blog/ipsen-to-acquire-kartos-for-450-million-upfront-in-myelofibrosis-deal 2026-07-17 monthly 0.7 https://melaneconsulting.ch/blog/ipsen-to-acquire-swiss-biotech-memo-therapeutics 2026-07-08 monthly 0.7 https://melaneconsulting.ch/blog/jasper-therapeutics-to-merge-with-kira-pharmaceuticals-in-132m-deal 2026-07-19 monthly 0.7 https://melaneconsulting.ch/blog/kelun-s-sac-tmt-adc-meets-phase-3-goal-in-pd-l1-negative-lung-cancer 2026-07-20 monthly 0.7 https://melaneconsulting.ch/blog/kimball-electronics-acquires-medical-cdmo-helvoet-for-90-million-euros 2026-07-19 monthly 0.7 https://melaneconsulting.ch/blog/life-sciences-primer 2026-07-08 monthly 0.7 https://melaneconsulting.ch/blog/lonza-expands-strategic-biologics-collaboration-with-major-us-pharma-p 2026-07-01 monthly 0.7 https://melaneconsulting.ch/blog/lonza-to-expand-commercial-adc-payload-linker-and-hpapi-capacity-at-vi 2026-07-01 monthly 0.7 https://melaneconsulting.ch/blog/medicare-begins-covering-glp-1s-for-obesity-from-1-july-50-monthly-cop 2026-07-01 monthly 0.7 https://melaneconsulting.ch/blog/annex-22-readiness-service 2026-07-01 monthly 0.7 https://melaneconsulting.ch/blog/merck-wins-fda-approval-for-lipfendra-the-first-oral-pcsk9-inhibitor 2026-07-17 monthly 0.7 https://melaneconsulting.ch/blog/novartis-fabhalta-wins-full-fda-approval-in-iga-nephropathy 2026-07-19 monthly 0.7 https://melaneconsulting.ch/blog/novartis-to-acquire-myricx-bio-for-up-to-1-5-billion-for-adc-payloads 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/novo-nordisk-wins-eu-approval-for-oral-wegovy-weight-loss-pill 2026-07-20 monthly 0.7 https://melaneconsulting.ch/blog/olon-doubles-us-api-capacity-and-adds-high-potency-suite-in-ohio 2026-07-17 monthly 0.7 https://melaneconsulting.ch/blog/onesource-and-formycon-sign-biosimilar-manufacturing-partnership 2026-07-19 monthly 0.7 https://melaneconsulting.ch/blog/orion-and-shilpa-partner-on-eu-gmp-nivolumab-biosimilar-for-europe 2026-07-17 monthly 0.7 https://melaneconsulting.ch/blog/peptide-cdmo-capacity-hits-a-five-year-high-cordenpharma-leads-with-a 2026-07-14 monthly 0.7 https://melaneconsulting.ch/blog/q32-bio-s-bempikibart-posts-positive-phase-2a-data-in-alopecia-areata 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/regenxbio-completes-confirmatory-dosing-for-rgx-202-duchenne-gene-ther 2026-07-02 monthly 0.7 https://melaneconsulting.ch/blog/restructuring-wave-takeda-cuts-us-staff-in-a-1-3-billion-plan-novartis 2026-07-01 monthly 0.7 https://melaneconsulting.ch/blog/roche-discontinues-two-huntington-s-disease-programmes 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/roche-s-divarasib-beats-lumakras-and-krazati-in-phase-3-lung-cancer 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/samsung-biologics-to-manufacture-astrazeneca-s-subcutaneous-saphnelo 2026-07-19 monthly 0.7 https://melaneconsulting.ch/blog/section-232-pharma-tariffs-july-31-deadline-nears-for-17-drugmakers 2026-07-16 monthly 0.7 https://melaneconsulting.ch/blog/sotio-s-cdh17-adc-sot109-wins-fda-fast-track-in-colorectal-cancer 2026-07-16 monthly 0.7 https://melaneconsulting.ch/blog/subcutaneous-sarclisa-escena-wins-fda-approval-via-on-body-injector 2026-07-17 monthly 0.7 https://melaneconsulting.ch/blog/switzerland-races-to-finalise-a-us-trade-deal-pharma-tariffs-capped-at 2026-07-11 monthly 0.7 https://melaneconsulting.ch/blog/takeda-and-insilico-medicine-sign-ai-drug-discovery-collaboration 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/ten23-health-wins-swissmedic-atmp-gmp-licences-for-basel-and-visp 2026-07-20 monthly 0.7 https://melaneconsulting.ch/blog/teva-takes-global-rights-to-a-polpharma-ocrelizumab-biosimilar 2026-07-20 monthly 0.7 https://melaneconsulting.ch/blog/uk-life-sciences-plan-draws-3-billion-pounds-trial-setup-times-fall 2026-07-20 monthly 0.7 https://melaneconsulting.ch/blog/us-reaches-most-favored-nation-pricing-deals-with-17-large-drugmakers 2026-07-10 monthly 0.7 https://melaneconsulting.ch/blog/vertex-to-buy-crinetics-for-10-billion-its-largest-deal-ever 2026-07-06 monthly 0.7 https://melaneconsulting.ch/blog/vistagen-s-fasedienol-misses-its-primary-endpoint-in-a-phase-3-social 2026-07-03 monthly 0.7 https://melaneconsulting.ch/blog/who-holds-the-audit-trail 2026-06-11 monthly 0.7 https://melaneconsulting.ch/blog/who-qualified-the-test 2026-06-25 monthly 0.7